ѻý

Novel Drug Better Than Wegovy? New Endocrine Society Prez; Knockoff Tirzepatide Woes

<ѻý class="mpt-content-deck">— News and commentary from the endocrinology world
MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

In a phase I trial, investigational amycretin compared with historical benchmarks set by semaglutide (Wegovy), according to drugmaker Novo Nordisk. (Forbes)

Use of the for type 1 diabetes led to 17.5% greater time spent in range (70 to 180 mg/dL) compared with insulin pump therapy in a trial, said maker Insulet.

The elected Carol Lange, PhD, of the University of Minnesota in Minneapolis, as its 2025-2026 president.

The Congressional Budget Office suggested that may soon be covered by Medicare, in part due to recent findings about heart benefits. (Endpoint News)

Bacteria and high levels of impurities were found in (Mounjaro, Zepbound). (Reuters)

Meanwhile, tirzepatide-maker urges against using weight-loss drugs for "vanity" reasons. (CNN)

Younger women exposed to neighborhood poverty in adulthood were more likely to have . (Menopause)

Girls are and earlier in recent years. (STAT)

New research is casting doubts about whether or not with symptoms of polycystic ovary syndrome. (New York Times)

appeared to reduce cancer mortality and raise cardiovascular disease mortality in post-menopausal women after more than 20 years of follow-up. (Annals of Internal Medicine)

One center for patents with obesity and end-stage renal disease by first having them undergo bariatric surgery. (Journal of the American College of Surgeons)

Elevated metabolic syndrome scores for long periods of time were associated with an , a prospective cohort study found. (Cancer)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.